InmazebActive Ingredient(s): Atoltivimab + Odesivimab + Maftivimab
FDA Approved: * October 14, 2020
Pharm Company: * REGENERON PHARMACEUTICALS
Atoltivimab/maftivimab/odesivimab, developed as REGN-EB3 and sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus). It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals. The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are al... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.